Quinolinic Acid Fuels Prostate Cancer Growth Through Key Biochemical Pathway

New research has uncovered a critical link between quinolinic acid and prostate cancer progression. The study reveals how this oncometabolite influences cancer cell behaviour through a specific biochemical pathway. Findings suggest potential for novel treatments targeting this mechanism. Scientists found that quinolinic acid, produced by the enzyme HAAO, enhances the activity of FDPS. This boosts androgen receptor (AR) signalling, a key driver of prostate cancer growth. The acid also promotes AR movement into the cell nucleus, increasing the expression of genes that support tumour survival and proliferation.

Using advanced molecular techniques, the team validated the role of HAAO-derived quinolinic acid in this process. Patient-derived xenografts and clinical data further confirmed the relevance of these findings. Inhibiting HAAO or reducing quinolinic acid production was shown to weaken FDPS-dependent AR signalling, slowing tumour growth.

The study highlights the HAAO-FDPS-AR axis as a potential universal target in cancers driven by steroid hormone receptors. Researchers propose that combining HAAO inhibition with existing anti-androgen therapies could combat treatment resistance. These findings bridge metabolic biochemistry and cancer signalling, offering a new direction for prostate cancer treatment. The approach may improve outcomes by delaying or preventing resistance to current therapies. Clinical exploration of this pathway appears ready to begin.